Table 1.
Association between serum CCNY protein status and clinicopathological characteristics in NSCLC patients
| Group | Training set | Validation set | ||||
|---|---|---|---|---|---|---|
| Variables | No | CCNY+ (%) | P-value | No | CCNY+ (%) | P-value |
| Age (years) | ||||||
| ≤60 | 217 | 70 (32.3) | 0.196 | 56 | 32 (57.1) | 0.107 |
| >60 | 182 | 70 (38.5) | 44 | 18 (40.9) | ||
| Gender | ||||||
| Male | 273 | 101 (37.0) | 0.240 | 72 | 34 (47.2) | 0.373 |
| Female | 126 | 39 (31.0) | 28 | 16 (57.1) | ||
| Smoking history | ||||||
| Smoker | 240 | 88 (36.7) | 0.417 | 63 | 32 (50.8) | 0.836 |
| Non-smoker | 159 | 52 (32.7) | 37 | 18 (48.6) | ||
| Tumor location | ||||||
| Right | 165 | 58 (35.2) | 0.982 | 48 | 28 (58.3) | 0.109 |
| Left | 234 | 82 (35.0) | 52 | 22 (42.3) | ||
| Histologic subtype | ||||||
| A | 243 | 86 (35.4) | 0.874 | 48 | 23 (47.9) | 0.689 |
| S | 156 | 54 (34.6) | 52 | 27 (51.9) | ||
| pT status | ||||||
| pT1 | 39 | 16 (41.0) | 0.834 | 32 | 15 (46.9) | 0.976 |
| pT2 | 168 | 56 (33.3) | 43 | 22 (51.2) | ||
| pT3 | 55 | 19 (34.5) | 8 | 4 (50) | ||
| pT4 | 137 | 49 (35.8) | 17 | 9 (52.9) | ||
| pN status | ||||||
| pN0 | 87 | 13 (14.9) | <0.001a | 30 | 9 (30) | 0.022a |
| pN1 | 69 | 25 (36.2) | 24 | 13 (54.2) | ||
| pN2 | 124 | 47 (37.9) | 32 | 17 (53.1) | ||
| pN3 | 119 | 55 (46.2) | 14 | 11 (78.6) | ||
| pM status | ||||||
| pM0 | 220 | 63 (28.6) | 0.003a | 65 | 25 (38.5) | 0.002a |
| pM1 | 179 | 77 (43.0) | 35 | 25 (71.4) | ||
| pTNM stage | ||||||
| I | 46 | 6 (13.0) | 0.001 | 26 | 7 (26.9) | 0.006 |
| II | 65 | 17 (26.2) | 19 | 8 (42.1) | ||
| III | 109 | 40 (36.7) | 20 | 10 (50.0) | ||
| IV | 179 | 77 (43) | 35 | 25 (71.4) | ||
Note:
a
Statistically significant at P<0.05.
Abbreviation: NSCLC, non-small-cell lung cancer.